Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Pier Capital LLC

Pier Capital LLC boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 101.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,459 shares of the medical equipment provider's stock after acquiring an additional 30,961 shares during the period. Pier Capital LLC owned about 0.09% of Lantheus worth $4,935,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Texas Permanent School Fund Corp grew its holdings in Lantheus by 11.3% during the 2nd quarter. Texas Permanent School Fund Corp now owns 66,645 shares of the medical equipment provider's stock worth $5,351,000 after acquiring an additional 6,769 shares in the last quarter. PFG Investments LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at about $248,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Lantheus in the 2nd quarter valued at about $217,000. LSV Asset Management boosted its holdings in shares of Lantheus by 27.9% in the 2nd quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider's stock valued at $51,462,000 after buying an additional 139,647 shares in the last quarter. Finally, Torray Investment Partners LLC boosted its holdings in shares of Lantheus by 6.4% in the 2nd quarter. Torray Investment Partners LLC now owns 26,078 shares of the medical equipment provider's stock valued at $2,094,000 after buying an additional 1,560 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

LNTH traded up $2.87 during trading on Wednesday, reaching $101.95. 645,647 shares of the company's stock were exchanged, compared to its average volume of 1,029,078. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock has a market capitalization of $7.08 billion, a P/E ratio of 15.56 and a beta of 0.50. The company's fifty day simple moving average is $103.44 and its 200-day simple moving average is $82.08.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.68 by ($0.07). Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $394.10 million for the quarter, compared to analysts' expectations of $382.12 million. During the same period in the prior year, the business posted $1.40 earnings per share. The business's quarterly revenue was up 22.5% compared to the same quarter last year. As a group, research analysts predict that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price target on the stock. JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a report on Thursday, August 1st. Leerink Partners increased their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Finally, Truist Financial decreased their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and an average target price of $126.00.

Insiders Place Their Bets

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Gerard Ber sold 15,500 shares of Lantheus stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares of the company's stock, valued at approximately $2,047,402.08. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company's stock, valued at $9,540,682.20. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,193 shares of company stock valued at $3,949,202. 1.50% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.